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Abstract
Objective: To describe current United Kingdom practice in assessment and management of patients with juvenile
localised scleroderma (JLS) compared to Paediatric Rheumatology European Society (PRES) scleroderma working
party recommendations.
Methods: Patients were included if they were diagnosed with JLS and were under the care of paediatric
rheumatology between 04/2015–04/2016. Retrospective data was collected in eleven UK centres using a
standardised proforma and collated centrally.
Results: 149 patients were included with a median age of 12.5 years. The outcome measures recommended
by the PRES scleroderma working party were not utilised widely. The localised scleroderma cutaneous
assessment tool was only used in 37.6% of patients. Screening for extracutaneous manifestations did not
meet recommendations that patients with head involvement have regular screening for uveitis and baseline
magnetic resonance imaging (MRI) brain: only 38.5% of these patients were ever screened for uveitis; 71.2%
had a MRI brain.
Systemic treatment with disease-modifying anti-rheumatic drugs (DMARDs) or biologics was widely used
(96.0%). In keeping with the recommendations, 95.5% of patients were treated with methotrexate as first-line therapy.
82.6% received systemic corticosteroids and 34.2% of patients required two or more DMARDs/biologics, highlighting
the significant treatment burden. Second-line treatment was mycophenolate mofetil in 89.5%.
Conclusion: There is wide variation in assessment and screening of patients with JLS but a consistent approach to
systemic treatment within UK paediatric rheumatology. Improved awareness of PRES recommendations is required to
ensure standardised care. As recommendations are based on low level evidence and consensus opinion, further
studies are needed to better define outcome measures and treatment regimens for JLS.
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Introduction
The hallmark of JLS is chronic inflammation in the skin
and soft tissues leading to fibrosis and eventually atrophy.
This process can lead to complications such as joint con-
tractures, limb length discrepancy and facial atrophy. The
disease can have significant psychological and functional
impact [1, 2]. However, the disease is not just confined to
skin and soft tissue. Around 22% of patients may have
extracutaneous manifestations including neurological,
musculoskeletal and ocular complications [3].
Optimal treatment for JLS is not known and there
have been few studies published [4–9]. First line treat-
ment for active JLS is often methotrexate, its use sup-
ported by a randomised placebo controlled trial (RCT)
and some observational studies [4–8]. Mycophenolate
mofetil (MMF) is often used, although evidence is re-
stricted to small case series [9]. A wide range of other
treatments are used off–label in refractory cases with
some suggestion of benefit [10–12]. Corticosteroids are
used in the majority of patients presenting or relapsing
with active JLS but there is wide variation of steroids
regimens used [10, 11].
The Paediatric Rheumatology European Society
(PRES) working party for scleroderma has produced rec-
ommendations for both diagnosis, assessment and man-
agement of JLS [13]. The aim of these recommendations
was to provide consensus-based guidelines for a disease
area with limited evidence base.
The aim of this national audit was to describe UK
current practice in assessment and management of JLS
in the context of PRES working party recommendations.
Patients and methods
Patients were included if they had a diagnosis of JLS,
were under 19 years at time of audit, and were under the
care of a paediatric rheumatologist between April 2015
and April 2016. UK Paediatric Rheumatology tertiary
centres (n = 14) were invited to take part and 11 centres
participated (Birmingham, Bristol, Edinburgh, Leeds,
Liverpool, London (Evelina London Children’s Hospital
and Great Ormond Street Hospital), Manchester, New-
castle, Nottingham, Sheffield).
PRES working party recommendations for assessment
and management of JLS [13] were used as audit stan-
dards. A standardised Microsoft Excel proforma was
used to collect relevant retrospective data regarding
demographics, disease, assessment, screening, manage-
ment and outcomes.
Data were analysed descriptively with numerical data
presented as medians and interquartile ranges (IQR),
and categorical data as frequencies.
In accordance with the UK National Health Service
Health Research Authority guidelines, ethical approval
was not required as this was a clinical audit.
Results
Demographic data and diagnoses
In total 149 patients were identified and included with a
female to male ratio of 1.9:1. Median age at diagnosis
was 7.2 years (IQR 5.0–10.0 years) and at time of audit
was 12.5 years (IQR 9.5–15 years).
The majority of patients (100/149) had linear sclero-
derma with 55/100 affecting the limb and 45/100 affect-
ing the head/face. Of the remaining 49 patients, 22/49
had plaque morphoea (17/22 defined as superficial and
5/22 as deep); 15/49 had generalised morphoea; 2/49
had pansclerotic disease; 10/49 had mixed disease. De-
tails of the anatomical area affected were not available.
Extracutaneous manifestations
A total of 10/149 (6.7%) patients had ophthalmic in-
volvement. Of these 3/10 had uveitis including one pa-
tient with non-facial JLS and two patients with
associated eyelid/eyelash involvement; 1/10 had episcler-
itis (with associated eyelid/eyelash involvement) and 6/
10 had eyelid/eyelash involvement with no uveitis or
episcleritis.
There were 8/149 patients (5.4%) with neurological in-
volvement: 2/8 had central nervous system (CNS) vascu-
litis (both had seizures and abnormal MRI and
electroencephalograms, one patient also had headaches);
1/8 had seizures, headaches and abnormal MRI without
identified CNS vasculitis; 5/8 patients suffered headaches
in the absence of identified CNS vasculitis or seizures.
Six of the eight patients with neurological involvement
had linear scleroderma of the head/face with associated
en coup de sabre.
There were 6/149 patients (4.0%) with synovitis: 4/6
had oligoarthritis at the site of skin lesion; 1/6 had poly-
arthritis which included the site of the lesion and 1/6
had oligoarthritis away from the site of the lesion.
The majority of patients were described as having deep
involvement of subcutaneous tissue, muscle or bone:
113/149 (75.8%) had subcutaneous involvement, 27/149
(18.1%) had muscle involvement and 16/149 (10.7%) had
bone involvement. Joint contractures were seen in 30/
149 (20.1%) patients with 20/149 (13.4%) having limb
length discrepancies; 15/149 (10.1%) had gait abnormal-
ity and 11/149 (7.4%) had an impact on hand function.
There were 14/149 (9.4%) patients with involvement of
the dental/oral area and of those five had temporoman-
dibular joint involvement. Four patients (2.7%) had in-
volvement of the breast area.
Assessment of disease activity
Table 1 shows the PRES scleroderma working party rec-
ommendations our study population was audited
against, together with the number of patients who met
each of the recommendations.
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Use of assessment tools and imaging
Use of physician global assessment of activity
(PGA-A) [14] occurred in 81/149 (54.4%) and local-
ised scleroderma cutaneous assessment tool (LoSCAT)
[14] in 56/149 (37.6%). Thermography was used in
34/149 (22.8%); ultrasound in 11/149 (7.4%); laser
doppler in 5/149 (3.4%).
Screening for extra-cutaneous manifestations
Uveitis screening was performed in 35/149 (23.5%) of
patients: 13/35 (37.1%) had a single screen; 18/35
(51.4%) had screening at regular intervals; 4/35 (11.4%)
had screening on more than one occasion at irregular
intervals.
Of those with known craniofacial involvement, only
one patient received uveitis screening as frequently as
recommended, 11/52 (21.2%) received annual screening
and 32/52 (61.5%) were never screened.
Management
Table 2 summarises treatments used in our population.
Systemic treatment
All but six patients were managed with systemic
treatments (Table 2); of these six patients, three pa-
tients had superficial plaque morphoea managed with
topical therapy alone and three patients had inactive
disease.
Methotrexate was given as the first-line treatment in
127/133 (95.5%); information on the first-line DMARD
was unknown in 10 patients. MMF was the most com-
monly used second-line treatment (34/38, 89.5%). A
number of other DMARDs/biologics were used as sec-
ond, and third line agents. No patients in our cohort re-
ceived abatacept.
Use of allied health professionals
A total of 44/149 (29.5%) patients received physio-
therapy and 26/149 (17.4%) received occupational
therapy at least once. 29/149 (19.5%) had been seen
by a psychologist at some point during their disease
course.
Table 1 PRES scleroderma working group recommendations assessed within UK audit
Recommendation Number of patients meeting
recommendation (%)
Extra-cutaneous manifestations
In craniofacial JLS, brain MRI is recommended 37/52 (71.2%)
In craniofacial JLS, uveitis screening every 6 months is recommended for the first 4 years of the disease 1/52 (1.9%)
In non-facial JLS, uveitis screening every 12 months is recommended for the first four years 6/97 (6.2%)
Dental assessment is suggested for any child with craniofacial JLS 12/52 (23.1%)
Assessment
All patients with JLS, except for those with solitary small superficial plaque scleroderma, should be seen at
baseline and minimum of every 12months by a paediatric rheumatologist and (paediatric) dermatologist,
ideally in a combined clinic
107/149 (71.8%)a
PGA-A, PGA-D and the LoSCAT, are acceptable tools for capturing cutaneous disease activity and damage 83/149 (55.7%)b
PROMs should be considered as an adjunct to clinical outcome measures and the following are
recommended for serial measurements: Child/parent global assessment of disease severity on a visual
analogue scale of 0–10 cm; Children’s Dermatology Life Quality Index
86/149 (57.7%)c
Treatment
All types of active JLS require systemic immunosuppression, except for circumscribed small superficial
non-progressive lesions, which are not crossing a joint and occur in non-cosmetically sensitive areas,
where topical treatments alone may be appropriate
143/143 (100%)
First line treatment should be with methotrexate 15 mg/m2/week, max 25mg/week either orally or
subcutaneously
127/133 (95.5%)e
Bridging therapy with glucocorticoids should be used for patients requiring immunosuppression,
particularly in rapidly progressive and severe disease, such as lesions crossing the joints and
cosmetically disfiguring disease.
123/143 (86.0%)
Physiotherapy and/or occupational therapy are recommended for any patients with decreased range
of motion in any joints
24/30 (80.0%)d
JLS Juvenile localised scleroderma, PGA-A Physician global assessment-activity, PGA-D Physician global assessment-damage, LoSCAT Localised scleroderma
cutaneous activity tool, PROM Patient-reported outcome measures, MMF Mycophenalate mofetil, ETN Etanercept, ANA Anakinra, TCZ Tocilizumab
aAudit only recorded whether shared care clinic dermatology/rheumatology
bPatients where at least one of PGA-A, PGA-D or LoSCAT was used
cPatients where at least one form of PROM was used
dPatients with joint contractures
e data unavailable for 10 patients
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Other treatments
Light therapy (either psoralen+UVA or UVA or UVB)
was given to 5/149 (3.4%) patients of which four had lin-
ear disease (3 limb, 1 facial) and one had generalised
morphoea. Light therapy was not used as recommended
in all five patients (recommended for extending circum-
scribed superficial lesions; preferentially in children
above the age of 12; preferably UVA-1 or UVB narrow-
band, PUVA therapy should be avoided).
17/149 (11.4%) had had surgery including fat trans-
plants (10/149) and limb lengthening surgery (3/149).
Data was insufficient to identify whether disease was in-
active at this stage.
Outcomes
Over two-thirds of patients had achieved inactive disease
at the point of review (108/149, 72.5%). Just over half
(63/108, 58.3%) were still on systemic treatment. Add-
itionally; 69/148 (46.6%) of patients had had at least one
episode of drug free remission (data were missing for
one patient).
Discussion
This is the largest study to date to systematically audit
practice for assessment and treatment of JLS in the UK.
It highlights the significant disease and treatment burden
for JLS patients within the UK.
Assessment of disease is primarily by clinician assess-
ment. Use of other more standardised assessment tools,
such as LoSCAT, is much more variable. The LoSCAT is
a widely available bedside tool which has been validated
in JLS [15]. Further training for paediatric rheumatolo-
gists and dermatologists on the LoSCAT may facilitate
wider use of this tool and provide more standardised as-
sessment of disease activity and damage.
Inactive disease was not defined for this study as a
standardised approach to assessment was not seen
across sites. Therefore, inactive disease was based on
clinician opinion on note review. In 83/149 cases this in-
cluded mLoSSI and/or PGA-A scoring.
Screening for CNS and eye involvement in those with
craniofacial lesions is often not performed in the UK
despite PRES working party recommendations. This may
lead to under-recognition of extra-cutaneous features.
However, MRI scans were performed more often in pa-
tients with known craniofacial involvement diagnosed
after the implementation of the guideline (22/29) com-
pared to those diagnosed prior (15/23). Where uveitis
screening is performed there is no consistency in the fre-
quency, and screening does not meet PRES working
party recommendations. There may be a number of rea-
sons for this omission, including possible limited re-
sources, limited awareness of ophthalmology services
and lack of evidence on the risk of uveitis in JLS
[13]. Uveitis screening recommendations are largely
consensus driven. Pending further studies to define
uveitis rates, the authors agree that the PRES consen-
sus based recommendations on uveitis screening
should be followed within the UK.
This work highlights the significant treatment burden
to JLS patients with 96.0% requiring treatment with at
least one DMARD or biologic therapy and 34.2% receiv-
ing two or more. This finding may in part be due to se-
lection bias, as this study only reviewed patients
managed by paediatric rheumatologists while those with
milder disease responding to topical treatment alone
may be managed by a dermatologist alone.
Previous studies have highlighted the difference in prac-
tices between paediatric rheumatologists and dermatolo-
gists [14]. Shared care review by paediatric rheumatologists
Table 2 Table summarising treatments used
Systemic treatments Systemic CS Topical
treatments
MTX MMF TCZ ADA AZA ETN ANK CiC IV PO CS Vit D Tac




16.0 (9.3–24) 13.0 (6.0–25.5) 17.5 (15.8–24.0) 26.3 14 n/a 31 n/a 7.0 (3.5–10) 9.3
Previous
treatment
No of patients 79 17 0 0 0 4 0 2 106 49 48 14 22
Remissiona 34 5 n/a n/a n/a 0 n/a 0 103a 45a
Inefficacy 8 6 n/a n/a n/a 3 n/a 2 0 3
Intolerance 37 6 n/a n/a n/a 1 n/a 0 3 1
Never given No of patients 7 102 141 146 148 145 148 147 35 97 97 132 123
MTX Methotrexate, MMF Mycophenolate mofetil, TCZ Tocilizumab, ADA Adalimumab, AZA Azathioprine, ETN Etanercept, ANK Anakinra, CiC Ciclosporin, IV
Intravenous, PO Oral, CS Corticosteroid, Vit D Vitamin D analogue, Tac Tacrolimus, IQR Interquartile range
aPatients treated with steroids were often given a standard treatment course whilst being established on a DMARD/biologic which is stopped after a standard
interval according to local protocol rather than remission
The indication for commencement of a biological was not captured in this audit. A biological may have been commenced for refractory skin involvement or extra-
cutaneous manifestations such as uveitis, CNS involvement or synovitis
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and dermatologists is widely practiced in the UK as recom-
mended. Such collaborative care should greatly benefit pa-
tients by standardising management, and provide both
rheumatology expertise, particularly related to extra-cuta-
neous manifestations, and dermatology expertise such as
skin examination skills. Additionally, combined clinics may
provide greater opportunity to consider topical treatments
and phototherapy, which may be appropriate in some pa-
tients but with which many paediatric rheumatologists have
little experience.
There is a widely consistent approach to use of sys-
temic treatments for JLS within the UK. Most patients
are managed with methotrexate as first-line treatment
with bridging corticosteroid treatment as suggested by
the PRES working group. However, intolerance leading
to change in therapy remains a significant problem and
is much higher in this cohort than reported in clinical
studies in JLS [4, 16]. Whilst MMF is most often used as
second-line treatment there remains limited evidence as
to whether it is the most appropriate medication. Work
is needed to determine its efficacy in JLS [9]. This study
did not assess the details of steroid regimes in different
centres; however, it did demonstrate variation between
intravenous and oral corticosteroid use as demonstrated
in previous studies [11].
Light-based therapies are only recommended for pa-
tients in a very small subgroup of patients with mild dis-
ease by the PRES scleroderma working group. This is
supported by a recent meta-analysis comparing metho-
trexate and UVA/PUVA which demonstrated both had
favourable effect but methotrexate was significantly su-
perior to UVA/PUVA [17]. Four of the five children who
received light therapy had received 2 or more DMARDs/
biologics and had widespread and refractory disease.
The use of light-based therapies in this group is not cov-
ered by these recommendations or by the aforemen-
tioned meta-analysis. Light based therapies, used in
conjunction with a dermatologist with expertise, may
have a role in patients with refractory and more exten-
sive disease.
Physiotherapy, occupational therapy and psychological
therapy are not widely used in JLS patients in the UK.
Almost half of patients were not assessed using PROMs.
Wider use of PROMs, including quality of life scores
such as the Children’s Dermatology Life Quality Index
(CDLQI) [18] may aid clinician assessment of the impact
of the disease on patients. The use of PROMs could
highlight those patients who would benefit from input of
allied health professionals, leading to improved function
and quality of life for these patients.
This study is limited by only reviewing JLS patients
managed by paediatric rheumatologists. Further work to
understand how many patients are managed elsewhere
would help define the wider spectrum of disease. Whilst
data was collected from a large number of centres and
this is a significant strength of the study, it was not pos-
sible to collect data from all tertiary paediatric rheuma-
tology centres across the UK.
Lack of awareness of the PRES working party recom-
mendations is likely to have impacted on the findings of
this study. Upcoming European recommendations on
management of JLS via the Single Hub and Access point
for paediatric Rheumatology in Europe (SHARE) initia-
tive are in progress, which are likely to support a more
standardized approach to disease assessment and man-
agement [19]. Such recommendations should lead to
more equitable care and facilitate further studies to im-
prove our understanding of this disease.
Conclusion
In summary, this study demonstrates the significant dis-
ease and treatment burden for JLS patients in the UK. It
shows a wide variation in the assessment and screening of
JLS patients, but a consistent approach to systemic treat-
ment within the UK with care of the majority of patients
shared by paediatric rheumatologists and dermatologists.
Improved awareness of PRES recommendations and
future SHARE recommendations is required to ensure
standardised care. As such recommendations can now
only be based on low level evidence and consensus opin-
ion, further studies are needed to better define outcome
measures and treatment regimens for JLS.
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